12/3
08:30 am
artl
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical
Medium
Report
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical
11/19
11:02 am
artl
Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at Maxim Group.
Low
Report
Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at Maxim Group.
11/12
01:24 pm
artl
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
08:48 am
artl
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/12
08:00 am
artl
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
11/7
01:12 am
artl
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
08:30 am
artl
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
High
Report
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
10/27
08:00 am
artl
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
Medium
Report
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
10/15
09:15 am
artl
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
Low
Report
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
10/3
03:30 pm
artl
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
04:05 pm
artl
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
Low
Report
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
9/30
08:30 am
artl
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Low
Report
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
9/30
02:48 am
artl
Artelo Biosciences launches underwritten public offering to raise capital [Seeking Alpha]
Medium
Report
Artelo Biosciences launches underwritten public offering to raise capital [Seeking Alpha]
9/29
08:40 pm
artl
Artelo Biosciences Announces Proposed Underwritten Public Offering [Yahoo! Finance]
Medium
Report
Artelo Biosciences Announces Proposed Underwritten Public Offering [Yahoo! Finance]
9/29
07:15 pm
artl
Artelo Biosciences Announces Proposed Underwritten Public Offering
High
Report
Artelo Biosciences Announces Proposed Underwritten Public Offering
9/29
08:30 am
artl
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
Low
Report
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
9/10
09:12 am
artl
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms [Yahoo! Finance]
Low
Report
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms [Yahoo! Finance]
9/10
08:30 am
artl
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
Medium
Report
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
9/9
05:55 am
artl
Artelo Biosciences (NASDAQ:ARTL) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
Medium
Report
Artelo Biosciences (NASDAQ:ARTL) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
9/8
08:05 am
artl
Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
Low
Report
Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
9/5
04:05 pm
artl
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
Low
Report
Artelo Biosciences Announces Closing of $3.0 Million Public Offering